3rd Emirates Haematology Conference (EHC2013)
Venue: The Address Dubai Marina
|Event Date/Time: Mar 07, 2013||End Date/Time: Mar 09, 2013|
|Registration Date: Feb 27, 2013|
|Early Registration Date: Dec 15, 2012|
|Abstract Submission Date: Oct 15, 2012|
|Paper Submission Date: Oct 15, 2012|
Join EHC2013 for the UAE's most informative and complete Haematology conference for a great educational experience. Over three daysâ€”March 7 to 9, 2013â€”the latest research, case reports and statistics will be shared with Haematologists from around the world, examining the most recent medical advances, and engaging with some of the worldâ€™s leading experts in the field of Haematology. Delegates will be able to network with some of the best in the profession, build understanding into the future of Haematology and come away with a raft of new knowledge to prepare for new challenges in the field.
Vision: To create a knowledge-based environment where delegates from across all sub-specialties of Haematology can benefit from each otherâ€™s research, skills, and experience as a way to highlight the importance of Continuing Medical Education in the field.
Mission: The Mission of EHC2013 is to deliver a rich, advanced and informative scientific program with world renowned faculty presenting the latest statistics, case reports, research and medical advances in the field of Haematology.
Who should attend: The program is targeted at Haematologists, Paediatric Haematologists, Medical Oncologists, Paediatricians, Internists, Intern & Internal Medicine Residents and Medical Students. Allied Healthcare Professionals such as Nurses and Clinical Pharmacists interested and/or involved in related patient care are also encouraged to attend EHC2013 and benefit from the educational & networking opportunities offered.
The Scientific Committee welcomes the submission of abstracts for oral or poster presentations at EHC2013 from professionals, researchers and students in the Haematology field and related subspecialty fields.
Deadline for abstract submission is 15 October 2012, 8pm local UAE time.
Guidelines for Abstract Submission
A special criterion for accepting abstracts will be their topic as well as structure, content and degree of innovation.
Structure of the Abstract
The structure of the abstract should be as follows:
a. Background and Purpose
Please note that a maximum of 300 words is permitted. The titles and the names of the authors are excluded from this number and have to be entered separately. Tables should not be included in the abstract body.
Methods section should include type of statistical analysis done if applicable to the study.
Statements such as "Results will be discussed" are not acceptable and may lead to a rejection of the abstract.
1. Red Blood Cells and Iron; Physiology and Disease (Anemia)
3. Acute Lymphoblastic Leukemia
4. Acute Myeloid Leukemia
5. Chronic Lymphocytic Leukemia and Related Disorders
6. Chronic Myeloid Leukemia
7. Hodgkin's Lymphoma
8. MDS and Bone Marrow Failure Syndromes including PNH
9. Myeloma and other Monoclonal Gammopathies
10. Myeloproliferative Disorders
11. Non-Hodgkin's Lymphoma
12. Stem Cell Transplantation
13. Cytogenics and Molecular Diagnostics
14. Drug Resistance and Pharmacology
15. Genomics and Proteomics
16. Novel Therapeutics, Targeted Therapies and Gene Therapy
17. Infectious Diseases, Supportive Care
18. Platelets and Thrombocytopenia
19. Bleeding Disorders (Congenital and Acquired)
21. Quality of Life, Palliative Care and Ethics
By submitting the abstract, the author confirms and agrees to the following:
a. All authors approve submitting this work for presentation.
b. The authors have done the work reported in the abstract and take full responsibility for the contents.
c. The authors transfer all copyright ownership of the abstract to the EHC2013.
d. The authors agree to confine their presentation to information in the abstract.
e. At least one author will be available to present the abstract if selected for the program.
f. The author will immediately notify the EHC2013 Scientific Committee if they are unable to make a presentation or if the presenting author must be changed.
g. The authors guarantee that clinical studies and any animal tests have proceeded with the official permission from the proper authorities.
h. All presenters will be responsible for their own registration fees, hotel and travel expenses. We regret that we cannot waive registration fees or cover expenses for any oral or poster presenters.
15th June 2012: Abstract submission opens for free papers/posters
15th October 2012: Abstract submission deadline
18th Nov 2012: Abstract acceptance notification to first authors
7th Mar 2013 :EHC2013 begins